DEA registers 900+ medical dispensaries, then limits who they can trade with

For the first time, the federal government has formally registered state-licensed medical cannabis dispensaries. The Justice Department said on 30 October that the DEA had granted registration to more than 900 dispensaries operating in seven states: Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia.

The approvals are the first concrete result of the order Attorney General Todd Blanche signed in April, which moved state-licensed medical marijuana from Schedule I to Schedule III and opened a fast-track registration process for producers, manufacturers and distributors. The department did not name the approved businesses, but several large operators confirmed their own registrations within days.

Who got in, and who is waiting

The 900-plus registrations are a fraction of the queue. A list the DEA published the same day shows close to 7,000 dispensaries, manufacturers and distributors have applied. To qualify, each applicant has to clear a pre-registration investigation and meet the agency's standards for security, recordkeeping and inventory control, the same safeguards that apply to any controlled substance.

Florida, the largest market on the list, dominates the early disclosures. Trulieve said on 2 November that its medical dispensaries were among the first batch registered; it had filed its applications in April. Vireo Growth said the same day that all 41 of its Florida dispensaries had been registered. Jushi Holdings, which applied on 28 May, said on 3 November that it had received registrations for some of its medical operations, without saying which. Curaleaf said in its third-quarter results that it has started receiving registrations as well.

None of these companies has disclosed how many of its facilities beyond retail are covered, which matters because a dispensary that is registered still needs registered suppliers behind it.

The supply-chain catch

Registration comes with a condition that could reshape trading relationships quickly. Under DEA guidance, registered medical businesses may only buy from and sell to companies that have also been registered or that applied on time. They have until late November to bring their sourcing into line.

In practice, that pushes registered operators to cut ties with unregistered growers, processors and brands, and gives early approvals a commercial edge. Vertically integrated multi-state operators, which control their own cultivation and processing, are best placed to comply. Smaller suppliers that have not applied, or that sit at the back of the queue, risk losing customers in the weeks ahead.

Adult-use states are largely shut out

The DEA has also drawn a hard line around which programs it can work with. It says it cannot register medical businesses in states that issue dual licenses covering both medical and recreational sales, or in states that let patients qualify through self-certification.

That excludes a large part of the market. Two dozen states and Washington, D.C. allow adult-use cannabis, and many of them run medical and recreational sales through the same licensed businesses. Of the 40 states with medical programs, the seven in the first round are all medical-only. For now, the federal benefits of rescheduling flow mainly there.

The first federal registrations reward medical-only states and vertically integrated operators. Mature adult-use markets are, for now, watching from the sidelines.

The tax prize, still without a rulebook

The biggest financial change is on the tax side. While marijuana sat in Schedule I, Section 280E of the tax code barred state-licensed businesses from deducting ordinary costs such as rent, advertising and sales staff. Treasury and the IRS said the day after the April order that moving to Schedule III generally removes that bar, and that guidance would follow. According to NORML's summary of the announcement, that guidance is expected to limit 280E to any remaining Schedule I activity for companies with mixed operations, and to apply the change from the full tax year that contains the order's effective date.

The formal guidance has been slow to land. Holland & Hart noted in August that Treasury had announced its intention but not yet published anything, and Missouri regulators have since described operators' confusion over how and when the relief applies. There is also a live debate over whether DEA registration is required to claim it: Holland & Hart's reading is that the tax relief and the registration pathway are separate, but that holding a registration strengthens a company's position if the IRS challenges a return. Adult-use operations remain in Schedule I and stay subject to 280E.

Two legal fights still running

The April order is being challenged in the U.S. Court of Appeals for the D.C. Circuit, in consolidated cases led by Smart Approaches to Marijuana. Petitioners include anti-legalization groups, MMJ International Holdings and the attorneys general of Indiana and Nebraska. The court declined in September to freeze the order while the case proceeds, but it has not ruled on the merits. Under a briefing timetable the parties proposed in October, the challengers' opening brief would be due on 24 November and final briefs in February 2027, with oral argument sought before the court's summer recess. Holland & Hart has flagged the obvious risk: if the order were stayed or vacated, 280E would apply again across the industry.

Separately, a DEA administrative judge, Derek Julius, is weighing whether to move all marijuana, not just state-licensed medical products, to Schedule III. He refused to reopen hearings over a Government Accountability Office report that found gaps in how controlled substances are evaluated, but admitted the report and allowed short briefs on its weight. The government has asked him to give it no weight; replies were due on 5 November.

Reaction and open questions

Patient advocates welcomed the move. Americans for Safe Access founder Steph Sherer described the registrations as a major win for patient access, noting they landed days before the 30th anniversary of California's medical marijuana law. Chris Lindsey of the American Trade Association for Cannabis and Hemp called it a positive step, while saying the industry is watching closely what registered companies will be required to do.

Several practical questions remain. Schedule III businesses are normally regulated very differently from state cannabis licensees, and it is not yet clear which federal requirements will apply day to day. Many states let people with certain criminal records own or work in licensed businesses, and it is unclear whether the DEA will accept that. The agency has also not explained how it will treat companies that run both medical and recreational operations.

What to watch

Four things will shape the next few months: the late-November deadline for registered businesses to rework their supply chains; the pace at which the DEA works through the remaining applications; the challengers' opening brief in the D.C. Circuit, proposed for 24 November; and the IRS guidance that tells operators how to claim deductions. Watch, too, for the administrative judge's next step on broader rescheduling, and for pressure from adult-use states that want a path into the federal system.